+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Embolic Protection Device Market - Forecasts from 2021 to 2026

  • PDF Icon


  • 110 Pages
  • May 2021
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5351038
The embolic protection devices market is expected to grow at a compound annual growth rate of 7.63% over the forecast period to reach a market size of US$1,278.309 million in 2026 from US$764.000 million in 2019.

Embolic protection devices (EPDs) are primarily used during percutaneous cardiac procedures. They aid in reducing the number of complications arising due to blockages in small blood vessels caused by the debris that is released into the bloodstream. Embolic protection devices capture the blood and luminal debris within saphenous vein grafts during stenting, thereby inhibiting the distal embolization. These devices are considered a part of the most reliable, evidence-based procedure for reducing periprocedural myocardial infarction and other major cardiovascular events. This procedure is always accompanied by imaging systems to ensure the proper placement of the device. According to expert opinion, there is no doubt that these devices are therefore an important part of the procedure. There is already some evidence that the use of embolic protection devices during carotid and saphenous vein graft interventions significantly reduces the peri-procedural complication rates. Furthermore, reports of single-center clinical series performed in native coronary arteries and renal arteries suggest that the use of embolic protection may increase the safety of these procedures. However, due to the considerably low complication rates of these interventions even without the use of embolic protection devices, large randomized trials are needed to statistically prove the clinical efficacy of these devices. Rising cases of cardiovascular, peripheral, and neurovascular surgeries and heavy investments in the R&D of embolic devices are the prime factors propelling the market growth. The rise in the number of Trans-catheter Aortic Valve Replacement (TAVR) procedures and consumer awareness regarding embolic devices are also contributing toward market development. In addition, government bodies along with Non-Governmental organizations (NGOs) and educational institutes across various regions are engaged in spreading awareness about cardiovascular and neurovascular diseases and their possible treatment by launching awareness programs. This factor is also contributing toward the market expansion.

However, the presence of alternatives treatments, such as the use of drugs, and the high cost of medical devices may impede the market growth.

Growth Factors
  • Increasing prevalence of cardiovascular diseases.

The increasing prevalence of cardiovascular diseases (CVDs) represents one of the key factors driving the market growth. According to American Heart Association, more than 92 million Americans are living with some form of cardiovascular disease, further accounting for around 2,300 deaths in America each day. Additionally, according to the World Heart Federation (WHF), annually 15 million people suffer from a stroke. Increasing cases of cardiovascular disorders worldwide due to the growing geriatric population is also expected to support this market growth with the World Health Organization (WHO) estimating the population aged above 60 years to reach 1.6 billion by 2050. EPDs are crucial in reducing complications arising due to blockages in small blood vessels caused by the debris that is released into the bloodstream. They form a part of the most reliable, evidence-based procedure for reducing periprocedural MI and other major cardiovascular events. Thus, increasing the adoption of embolic protection devices to capture and remove debris that may be extricated during procedures are factors that will accelerate the embolic protection devices industry growth in the forthcoming years.

Impact of COVID - 19

With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.

Key Developments

April 2021-Novel Carotid Stent Provides Integrated Embolic Protection. The Contego Medical (Raleigh, NC, USA) Neuroguard integrated embolic protection (IEP) system is intended to improve luminal diameter in patients with clinically significant carotid artery stenosis, with simultaneous capture and removal of embolic material during angioplasty and stenting. The Neuroguard IEP System has received to European Community CE mark of approval, following a study involving 67 patients with one-year follow-up that showed an overall success rate of 100%, with a stroke and death rate of 0% at 30 days

July 2020 - Keystone Heart, A Venus MedTech Company, Announces First Commercial Case Performed Worldwide with The TriGUARD 3™ Cerebral Embolic Protection Device.

Competitive Insights

Prominent/major key market players in the embolic protection devices market include Abbott Laboratories, Boston Scientific Inc., Medtronic Plc., and Gore Medical among others. The players in the embolic protection devices market are implementing various growth strategies to gain a competitive advantage over their competitors in this market. Major market players in the market have been covered along with their relative competitive strategies and the report also mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered along with the recent deals and investments of these important players in the embolic protection devices market.


By Type
  • Occlusion Systems
  • Filter Systems

By Usage
  • Coronary Procedures
  • Peripheral Procedures
  • Carotid/Neurological Procedures
  • Renal Procedures

By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • the Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Taiwan
  • Others

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Embolic Protection Devices Market Analysis, By Type
5.1. Occlusion Systems
5.2. Filter Systems
6. Embolic Protection Devices Market Analysis, By Usage
6.1. Coronary Procedures
6.2. Peripheral Procedures
6.3. Carotid/Neurological Procedures
6.4. Renal Procedures
7. Embolic Protection Devices Market Analysis, By Geography
7.1. North America
7.1.1. United States
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Others
7.4. The Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Thailand
7.5.6. Indonesia
7.5.7. Taiwan
7.5.8. Others
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Abott Laboratories
9.2. Boston Scientific Inc.
9.3. Medtronic Plc.
9.4. Gore Medical
9.5. Cardinal Health
9.6. Innovative Cardiovascular Solutions
9.7. Emboline Inc.
9.8. NIPRO
9.9. Silk Road Medical
9.10. Keystone Heart (Venus MedTech)

Companies Mentioned

  • Abott Laboratories
  • Boston Scientific Inc.
  • Medtronic Plc.
  • Gore Medical
  • Cardinal Health
  • Innovative Cardiovascular Solutions
  • Emboline Inc.
  • Silk Road Medical
  • Keystone Heart (Venus MedTech)